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Lymphnode statusremainsoneofthemostuseful prognosticindicatorsinbreastcancer; however,current methodstoassessnodal
statusdisruptthelymphaticsystemandmayleadtosecondarycomplications.Identiﬁcationofmolecularsignaturesdiscriminating
lymph node-positive from lymph node-negative primary tumors would allow for stratiﬁcation of patients requiring surgical
assesment of lymph nodes. Primary breast tumors from women with negative (n = 41) and positive (n = 35) lymph node status
matched for possible confounding factors were subjected to laser microdissection and gene expression data generated. Although
ANOVA analysis (P<. 001, fold-change >1.5) revealed 13 diﬀerentially expressed genes, hierarchical clustering classiﬁed 90% of
node-negative but only 66% of node-positive tumors correctly. The inability to derive molecular proﬁles of metastasis in primary
tumors may reﬂect tumor heterogeneity, paucity of cells within the primary tumor with metastatic potential, inﬂuence of the
microenvironment, or inherited host susceptibility to metastasis.
1.Introduction
Breast cancer is the most common cancer in women from
Western countries. In 2009, approximately 190,000 women
in the United States were diagnosed with and more than
40,000 died from breast cancer [1]. Progression of malignant
breast cancer from localized to systemic disease can lead to
impaired organ function, widespread systemic failure, and
eventually, death. Five-year survival rates diﬀer dramatically
between women with negative lymph nodes (>90%)
compared to those with lymph node metastasis (<70%) [2].
Lymph node status is not only the most reliable predictor of
survival but is also critical in developing treatment regimens
[3].
Assessment of lymph node status was originally per-
formed by axillary lymph node dissection (ALND);however,
ALND is associated with signiﬁcant morbidities and has not
been associated with signiﬁcant survival advantage [4, 5],
thus alternate methods of evaluating lymph node status
have been developed. Sentinel lymph node biopsy (SLNB)
assesses lymph node status in the sentinel or ﬁrst-draining
nodes along the axillary lymph node chain; on average, two-
three lymph nodes are removed and patients with negative
lymph node status are spared complete axillary dissection.
Recent results from the NSAPB 32 and ACOSOG Z0011
trials demonstrated that in patients with node-negative
disease, SLNB is as eﬀective as ALND, and in patients
with positive nodes, despite the risk of axillary recurrence,
SLNB performed without follow up ALND is reasonable for
patients with early-stage breast cancer [6, 7].
AlthoughSLNBisassociated with lowermorbidities,sur-
gical disruption of the lymphatic system can result in serious2 International Journal of Breast Cancer
side eﬀects, including numbness, decreased mobility and
lymphedema, signiﬁcantly impacting the quality of life of
breast cancer patients. For example, lymphedema can result
in pain, decreased functional ability, cosmetic deformities
andpsychologicalstress[8]andisestimatedtoaﬀect10–20%
ofbreastcancersurvivors[9].Inaddition,SLNBisassociated
with a false negative rate of 8–10% [4, 10]. Development of
a signature that eﬀectively discriminates patients by lymph
nodestatuscouldstratify patientsintothoseneedingsurgical
evaluation of the lymph nodes for prognostic purposes from
those at low risk of metastasis who may be spared possible
serious side eﬀectsas well as identify those 8–10%ofpatients
misdiagnosed with negative lymph node status after SLNB,
who may in fact beneﬁt from more aggressive treatment.
In this study, microarray-based gene expression analysis was
performed on primary breast tumors from patients with
and without metastatic lymph nodes to identify molecular
signatures associated with lymph node metastasis.
2.Materialsand Methods
2.1. Tissue Samples. Tissue samples in the Clinical Breast
Care Project (CBCP) tissue bank were collected with
approvalfromtheWalterReedArmy MedicalCenterHuman
Use Committee and Institutional Review Board. All subjects
enrolled in the CBCP voluntarily agreed to participate and
gave written informed consent. Clinical information was
obtainedforallCBCPsamplesusingquestionnairesdesigned
by and administered under the auspices of the CBCP.
The CBCP database was queried to identify all patients
diagnosed with invasive breast cancer between 2001 and
2008. Patients with a previous history of breast cancer, doc-
umented BRCA1 or BRCA2 mutations, or who underwent
neoadjuvant therapy were not eligible for this study. Patients
with isolated tumor cells or micrometastases as well as those
diagnosed with negative lymph node status who later died of
disease were excluded from analysis. To ensure consistency,
diagnosis of every specimen was made by a single breast
pathologist from hematoxylin and eosin (H&E) stained
slides; grade was assigned using the Nottingham Histologic
Score [11, 12]. ER and PR status were determined by
immunohistochemistry by a commercial clinical laboratory
(MDR Global, LLC, Windber, PA, USA); HER2 status was
determined by ﬂuorescence in situ hybridization using the
PathVysion HER2 kit according to manufacturer’s protocol
(Abbott Laboratories, Abbott Park, IL, USA).
2.2. RNA Isolation, Ampliﬁcation, aRNA Labeling and Hybri-
dization. For each case, hematoxylin- and eosin-stained
slides were examined by a dedicated breast pathologist and
tumor areas marked for laser microdissection. One to six
serial sections (8µm thick) were cut, mounted on glass
PEN foil slides (W. Nuhsbaum, Inc., McHenry, IL, USA),
stained using the LCM staining kit (Applied Biosystems,
Foster City, CA, USA) and microdissected on an ASLMD
laser microdissection system (Leica Microsystems, Wetzlar,
Germany). Slide preparation, staining and cutting were
performed within 15 minutes to preserve RNA integrity.
RNA was isolated from laser microdissected tumor cells
using the RNAqueous-Micro kit (Applied Biosystems, Foster
C i t y ,C A ,U S A )a n dt r e a t e dw i t hD N a s eIt or e m o v ea n y
contaminating genomic DNA. RNA integrity was assessed
using the 2100 Bioanalyzer (Agilent Technologies, Santa
Clara,CA,USA).RNAwasconvertedtobiotin-labeledaRNA
using two rounds of ampliﬁcation with the MessageAmpII
aRNA Ampliﬁcation kit (Applied Biosystems, Foster City,
CA, USA), and the concentration and quality of the aRNA
samples measured with the NanoDropND-1000(NanoDrop
Products, Wilmington, DE, USA) and the 2100 Bioanalyzer,
respectively. Hybridization, washing, staining and scanning
were performed using the HGU133A2.0 arrays (Aﬀymetrix,
Santa Clara, CA, USA)according to manufacturer’s protocol.
2.3. Analysis and Statistics. Aﬀymetrix gene expression data
was imported into Partek Genomics Suite 6.5 (Partek, Inc,
St Louis, MO, USA) as CEL ﬁles using default Partek
parameters. Raw data was preprocessed, including back-
ground correction, normalization and summarization using
robust multiarray average (RMA) analysis and expression
data log2 transformed. Diﬀerential gene expression analysis
was performed using one-way ANOVA using lymph node
status as the variable. Gene lists were created using a cut-oﬀ
of P<. 001, >1.5-fold change. Hierarchical clustering was
performed using the Gene Expression module.
3.Results
3.1. Clinicopathological Characteristics. The average number
of metastatic lymph nodes in the node-positive group was
4.69 (range 1–19). The average age at diagnosis did not
diﬀer signiﬁcantly between those with (55.0 years) and those
without (57.7 years) lymph node metastasis. None of the
pathologicalfeatures evaluateddiﬀeredsigniﬁcantly between
groups (Table 1). To date, 24/39 (62%) of the node-negative
patients have been disease-free for ≥5y e a r sa n dn o n eh a v e
died of disease. In contrast, 6/35 (17%) of node-positive
patients died of disease with an average survival of 34
months, one (3%) has progressed from stage IIIa to stage IV,
and 47% have remained disease-free for at least ﬁve years.
3.2. Gene Expression. Statistical analysis revealed signiﬁcant
diﬀerencesin expression levelsfor15probesbetween tumors
frompatientswithlymphnodemetastasesandthosewithout
(Table 2). These genes correspond to 11 genes (KIAA1609
and SLC27A2 are each represented by two independent
probes) with known function, one uncharacterized gene and
one probe that represents a UniGene EST cluster only. These
results suggest that primary breast tumors with diﬀerent
metastatic capacities are more similar than diﬀerent in
gene expression as the small number of genes diﬀerentially
expressed does not diﬀer signiﬁcantly (P = .25) from what
wouldbeexpectedbychance.Hierarchicalclusteringanalysis
was able to correctly classify 4/41 (90%) of the lymph node-
negative tumors but only 23/35 (66%) of the node-positive
tumors (Figure 1).International Journal of Breast Cancer 3
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Figure 1: Heat map and hierarchical clustering of 76 primary tumor samples based on 15 diﬀerentially expressed probes. Tumors from
patients with negative lymph node status are represented in the dendrogram by blue bars and tumors from patients with positive lymph
node status are represented by red bars. 4/41 tumors with negative lymph nodes and 12/35 tumors with positive lymph nodes were classiﬁed
incorrectly. Red squares: high expression, blue: low expression.4 International Journal of Breast Cancer
Table 1: Clinical and pathological features of 76 invasive breast
tumor specimens used in microarray analysis.
Node
negative
(n = 41)
Node
positive
(n = 35)
Pn o d e −
versus node+
Age
<50 years 37% 34% NS
≥50 years 63% 66%
Histology
IDCA 95% 86%
ILCA 5% 9% NS
Mixed 0% 5%
Grade
Well-diﬀerentiated 27% 9%
Moderately-diﬀerentiated 29% 43% NS
Poorly-diﬀerentiated 44% 48%
Hormone receptor statusa
ER+/PR+ 54% 51%
ER+/PR− 22% 12% NS
ER−/PR− 24% 37%
HER2 Status
Positive 20% 26% NS
Negative 80% 74%
Tumor Size
T1 63% 42%
T2 34% 54% NS
T3 3% 4%
aNo cases of ER−/PR+ were identiﬁed in this group of tumors.
4.Discussion
Gene expression-based molecular signatures have been
developed that can be used to predict intrinsic subtype,
tumor grade, and risk of recurrence [13–15], each of which
can be used as a prognostic tool. Although a signature spe-
ciﬁc to the development of local metastases may not predict
overalloutcome,such a signature would havebothbiological
and clinical utility. Identiﬁcation of genes involved in the
successful establishment of metastatic tumors in the lymph
nodes would improve our understanding of the metastatic
process. Diﬀerentially expressed genes may represent those
involved in the initiation of metastasis, altering cell motility,
angiogenesis and invasion thus allowing primary tumor cells
with metastatic potential to disseminate [16]. These genes
would then serve as molecular targets against which novel
therapeutics could be developed to prevent the early stages
of metastasis. In addition, identiﬁcation of a signature of
metastasis would allow women at low risk of lymph node
metastasis to be spared unnecessary surgical procedures and
the ensuring complicationsof lymph node disruption as well
as to identify the 8–10% of node-positive women diagnosed
as node-negative by SLNB [17].
To this end, eﬀorts have been made to develop a breast
tumormolecular signature that diﬀersbetween patients with
and withoutlymph nodemetastasis. Forexample, evaluation
of gene expression patterns of 176 candidate genes between
primary tumors without lymph node metastasis and those
with 10 or more positive lymph nodes revealed diﬀerences
in gene expression, with signiﬁcantly higher expression of
ERBB2 (P<. 0001) in tumors from node-positive compared
to node-negative tumors [18]. From a pool of 89 primary
tumors, data from 19 primary tumors without lymph node
metastasis and 18 with ≥10 positive lymph nodes were
compared to generate a metagene proﬁle, enriched for genes
involved in cellular immunity, capable of predicting lymph
node status with 90% accuracy [19]. Finally, using Serial
Analysis ofGeneExpression in 27 invasive ductalcarcinomas
with either positive or negative lymph node status, 245
diﬀerentially expressed (P<. 05) genes were detected; these
results were validated in an independent set of tumors for
seven of the genes [20].
In contrast, a number of research groups have failed
to develop molecular signatures predictive of lymph node
metastasis. Gene expression data from 129 primary breast
tumors was used to successfully develop signatures corre-
lating expression patterns with grade and ER and HER2
status but a signature for lymph node status could not
be identiﬁed; the authors thus concluded that while there
may be a biological propensity to metastasize, the inﬂuence
of time and stochastic processes on tumor metastasis may
preclude the identiﬁcation of a signature of lymph node
metastasis [21].Inasecond studyevaluatingmicroarray data
from 151lymph node-negative and 144 lymphnode-positive
primary tumors, signiﬁcant gene expression diﬀerences were
not detected between tumor types. The authors then applied
the lymph node metastasis signature described previously by
Huang et al. to their own external data set and achieved a
classiﬁcation accuracy of only 50%, implying that the signa-
ture developedby Huang, using a small sample set and limit-
ing analysis topatients with ≥10 positive lymphnodes, isnot
an eﬀective predictor of nodal metastasis [22]. In addition,
while the 70-gene poor prognosis signature that is the basis
f o rt h eM a m m a P r i n ta s s a yi se ﬀective at predicting risk of
recurrence,it was ineﬀectiveinpredictinglymphnodestatus,
leading the authors toconcludethat hematogenous and lym-
phogenic metastases are driven by independent molecular
mechanisms [23]. Similar to these studies, the ﬁfteen probes
found in our study to be diﬀerentially expressed were not
eﬀective in correctly classifying primary tumors, especially
those with positive lymph nodes, by lymph node status.
A number of reasons may explain the discrepancy
between those groups that have reported molecular signa-
tures of lymph node metastasis and those that have failed to
ﬁnd gene expression diﬀerences. Study design may aﬀect the
ability to detect critical molecular alterations. Most studies
identifying a signature of lymph node metastasis relied on
small (<40samples) sample sizes. Breastcancerisnotasingle
disease but rather a complex mix of diﬀerent architectures,
grades and underlying subtypes which may necessitate the
use of large number of samples to generate robust signatures
[24]. In addition, multiple models were developed using
patients with extremely discordant (negative lymph node
status compared to ≥10 positive lymph nodes) phenotypesInternational Journal of Breast Cancer 5
Table 2: Fifteen probes demonstrating signiﬁcant diﬀerences in expression level between tumors with and without lymph node metastases.
KIAA1609 and SLC27A2 were represented by multiple probes.
Gene
symbol
Accession
number Gene name Probe ID P value Fold-change
Genes downregulated in node-positive primary tumors
ABCC8 NM 000352 ATP-binding cassette, subfamily C (CFTR/MRP),
member 8 210246 s at .000889 1.67
BATF NM 006399 Basic leucine zipper transcription factor, ATF-like 205965 at .000874 1.51
IGFBP6 NM 002178 Insulin-like growth factor binding protein 6 203851 at .000679 1.55
MRPL40 NM 003776 Mitochondrial ribosomal protein L40 203152 at 2.14E-05 1.57
SLC27A2 NM 003645 Solute carrier family 27 (fatty acid transporter),
member 2 205768 s at .000413 2.34
205769 at .000921 2.12
Genes upregulated in node-positive primary tumors
—a AL050145 215526 at .000477 1.55
AURKA NM 198433 Aurora kinase A 208079 s at .000512 1.80
KIAA1609 NM 020947 KIAA1609 221843 s at 1.25E-05 1.66
65438 at 1.53E-05 1.73
KIF23 NM 138555 Kinesin family member 23 204709 s at .000675 1.82
PLCB1 NM 015192 Phospholipase C, beta 1 (phosphoinositide-speciﬁc) 213222 at .000612 2.05
RPL13 NM 033251 Ribosomal protein L13 214976 at .000129 1.64
TCP1 NM 030752 T-complex 1 208778 s at .000183 1.51
TGFA NM 003236//
NM 001099691b Transforming growth factor, alpha 205016 at .000233 1.77
aThis probe corresponds to UniGene cluster HS.225986 but not to a known gene.
bThis probe represents both isoforms 1 and 2 of the TGFA gene.
[18,19];thesemodels, therefore,maynotapplytothemajor-
ity of patients who have an intermediate number of positive
lymph nodes [21]. Finally, validation of these signatures on
independent sample sets has, to our knowledge, not been
reported, and to date, while molecular portraits are used to
determine tumor grade, subtype and prognosis, no clinical
assay is available to determine lymph node status.
In addition to methodological concerns, lack of a
signature of lymph node metastasis may be attributable
to biological properties of primary breast tumors, such as
the nature and number of cells within a primary tumor
with metastatic potential. Injection of melanoma cells into
mice demonstrated that tumor cells vary widely in their
ability to produce metastases, and cells with metastatic
potential are rare within the primary tumor [25, 26]. This
view was challenged by the development of gene expression
signatures such as the 70-gene poor prognosis signature and
a molecular signature of metastasis developed from solid
tumors [15, 27]; because these signatures were derived from
bulk tumors, the authors concluded that the majority of
cells in the primary tumor have the ability to metastasize.
In fact, the ability to predict which tumors will metastasize
based on gene signatures derived from primary tumors does
not preclude the presence of small subpopulations of cells
with full metastatic potential found in localized regions
throughout the primary tumor [28, 29]. For example,
comparison of gene expression patterns between cell line
populations that have high compared to low metastatic
potential to bone revealed that only a small fraction of cells
demonstrated the full bone metastasis signature [30]. More
recently, the sequencing of a basal-like primary breast tumor
and corresponding brain metastasis revealed a signiﬁcant
enrichment of 20 mutations in the metastasis compared to
the primary tumor, suggesting that metastases arise from a
minority population of cells within the primary tumor [31].
If these models in which few cells within the primary tumor
have full metastatic capacity are correct, genetic signatures
from these rare cells will be masked by the majority of tumor
cells which do not have full metastatic capacity.
Molecularheterogeneity withintumorsubtypesmay also
precludethe identiﬁcationofa single signature ofmetastasis.
Breast tumors can be classiﬁed by their intrinsic subtypes,
including luminal A, luminal B, HER2-positive and basal-
like, based on diﬀerent patterns of gene expression [13].
These subtypes have been associated with diﬀerences in
relapse-free and overall survival with the basal-like and
HER2-positive subtypes having the shortest survival times
[32].Notonlydointrinsic subtypeshavediﬀerentprognoses,
but recent studies have shown that each subtype has
preferential sites of metastasis: bone was the predominant
site of relapse in luminal and HER2-positive tumors but
was infrequent in basal-like tumors. In contrast, basal-like
tumors had frequent relapse in brain, lung and distant
lymph nodes [33, 34]. Data supporting the idea that tumors
with diﬀerent phenotypes may metastasize diﬀerently was
provided by a recent study which found nonoverlapping6 International Journal of Breast Cancer
signatures for the development of distant metastasis in
lymph-node-negative ER-positive and ER-negative tumors,
suggesting that there are diﬀerent molecular mechanisms
associated with metastasis depending ontumorbiology[35].
Whether lymph node metastasis is similarly aﬀected by
tumor phenotypes such as ER status or intrinsic subtype
remains to be determined.
The ability to metastasize may be inﬂuenced by not only
the tumor cells but also the microenvironment, both local
and distant. Dissemination of tumor cells from the primary
site is one of the earliest steps of metastasis; successful
invasion and migration of tumor cells requires a number
of changes in the breast microenvironment including degra-
dation of the extracellular matrix and angiogenesis. Distant
tissue may be subjected to premetastatic niche conditioning,
undergoing changes such as recruitment of bone-marrow
derived cells that form a favorable environment for tumor
cells to grow. Finally, the last stages of metastasis require
tumors cells to successfully reach the secondary site, escape
senescence and survive and proliferate within a foreign
environment [16, 36]. Given the importance of the microen-
vironment, molecular characterization of the tumor com-
ponent alone may not be suﬃcient in predicting metastatic
behavior as a tumor with an aggressive proﬁle may be
growing within a nonpermissive microenvironment and vice
versa. In fact, many signatures of poor prognosis or metas-
tasis include the expression of stromal genes. Thus, consid-
eration of only the tumor epithelial component may fail to
capture the full metastatic potential of a primary tumor.
Finally, the ability to metastasize may depend not on
biologic features of the primary tumor but on inherent host
susceptibility. Outcrossing of a highly metastatic transgenic
mouse to a variety of inbred mouse strains resulted in
signiﬁcant variability in the propensity to metastasize; since
eachanimalreceivedthemetastatictransgene, thediﬀerences
in metastatic capacity have been attributed to genetic back-
ground [37]. Linkage studies identiﬁed candidate metastasis
modiﬁer genes in mouse, including SipaI [38]. Follow up
studies in humans conﬁrmed that SIPA1 is a metastasis
susceptibility gene [39, 40]. Thus, the ability to successfully
metastasize may, at least in part, reﬂect a systemic, rather
than tumor-driven, proclivity.
5.Conclusions
New molecular tools are needed that can eﬀectively discrim-
inate patients with and without the propensity to develop
lymph node metastasis so that women at low risk may be
spared potentially signiﬁcant morbidities associated with
surgical evaluation, and the false negative rate associated
with SLNB can be reduced. In this study, 15 probes, rep-
resenting 11 well-characterized and two hypothetical genes,
were diﬀerentially expressed between tumor types; however,
hierarchical clustering based on this gene signature was
ineﬀective, especially for the lymph node-positive tumors,
suggesting that a single molecular classiﬁer for lymph node
metastasis may not exist. The inability to derive molecular
proﬁles of metastasis in primary tumors may reﬂect tumor
heterogeneity,paucityofcellswithin theprimary tumorwith
metastatic potential, inﬂuence of the microenvironment, or
inherited host susceptibility to metastasis.
Acknowledgments
The authors thank Dr. Darrell Ellsworth for helpful and
critical review of this paper. This research was supported
by a Grant from the United States Department of Defense
(Military Molecular Medicine Initiative MDA W81XWH-
05-2-0075, Protocol 01-20006). The opinion and assertions
contained herein are the private views of the authors and are
not to be construed as oﬃcial or as representing the views of
the Department of the Army or the Department of Defense.
References
[1] American Cancer Society, Breast Cancer Facts and Figures:
2009–2010, American Cancer Society, Atlanta, Ga, USA, 2009.
[2] National Cancer Institute, SEER Cancer Statistics Review,
1973-1991, NIH Publ. No. 94-2789, NIH, Bethesda, Md, USA,
1994.
[ 3 ]P .E i f e l ,J .A .A x e l s o n ,J .C o s t ae ta l . ,“ N a t i o n a li n s t i t u t e so f
healthconsensusdevelopmentconferencestatement:adjuvant
therapy for breast cancer, November 1–3, 2000,” Journal of the
National Cancer Institute, vol. 93, no. 13, pp. 979–989, 2001.
[ 4 ]E .A .N e w m a na n dL .A .N e w m a n ,“ L y m p h a t i cm a p p i n g
techniques and sentinel lymph node biopsy in breast cancer,”
Surgical Clinics of North America, vol. 87, no. 2, pp. 353–364,
2007.
[5] B. Fisher, C. Redmond, E. R. Fisher et al., “Ten-year results of
a randomizedclinicaltrialcomparingradical mastectomyand
totalmastectomywithorwithoutradiation,”TheNewEngland
Journal of Medicine, vol. 312, no. 11, pp. 674–681, 1985.
[ 6 ]D .N .K r a g ,S .J .A n d e r s o n ,T .B .J u l i a ne ta l . ,“ S e n t i n e l -
lymph-node resection compared with conventional axillary-
lymph-node dissection in clinically node-negative patients
with breast cancer: overall survival ﬁndings from the NSABP
B-32 randomised phase 3 trial,” The Lancet Oncology, vol. 11,
no. 10, pp. 927–933, 2010.
[7] A. E. Giuliano, L. McCall, P. Beitsch et al., “Locoregional
recurrence after sentinel lymph node dissection with or
without axillary dissection in patients with sentinel lymph
node metastases: the American College of Surgeons Oncology
Group Z0011 randomized trial,” Annals of Surgery, vol. 252,
no. 3, pp. 426–432, 2010.
[ 8 ]L .A n d e r s e n ,I .H o j r i s ,M .E r l a n d s e n ,a n dJ .A n d e r s e n ,
“Treatment of breast-cancer-related lymphedema with or
without manual lymphatic drainage: a randomized study,”
Acta Oncologica, vol. 39, no. 3, pp. 399–405, 2000.
[9] G. H. Sakorafas, G. Peros, L. Cataliotti, and G. Vlastos,
“Lymphedema following axillary lymph node dissection for
breast cancer,” Surgical Oncology, vol. 15, no. 3, pp. 153–165,
2006.
[10] L. G. Wilke, L. M. McCall, K. E. Posther et al., “Surgical
complications associated with sentinel lymph node biopsy:
results from a prospective international cooperative group
trial,” Annals of Surgical Oncology, vol. 13, no. 4, pp. 491–500,
2006.
[ 1 1 ] H .J .B l o o ma n dW .W .R i c h a r d s o n ,“ H i s t o l o g i c a lg r a d i n ga n d
prognosis in breast cancer; a study of 1409 cases of which 359
have been followed for 15years,” British Journal of Cancer,v o l .
11, no. 3, pp. 359–377, 1957.International Journal of Breast Cancer 7
[12] C. W. Elston and I. O. Ellis, “Pathological prognostic factors
in breast cancer. I. The value of histological grade in breast
cancer: experience from a large study with long-term follow-
up,” Histopathology, vol. 19, no. 5, pp. 403–410, 1991.
[13] C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits
ofhumanbreasttumours,”Nature,vol.406,no.6797,pp.747–
752, 2000.
[14] C. Sotiriou, P. Wirapati, S. Loi et al., “Gene expression
proﬁling in breast cancer: understanding the molecular basis
of histologic grade to improve prognosis,” Journal of the
National Cancer Institute, vol. 98, no. 4, pp. 262–272, 2006.
[15] L. J. van’t Veer, H. Dai, M. J. van de Vijver et al., “Gene
expression proﬁling predicts clinical outcome of breast can-
cer,” Nature, vol. 415, no. 6871, pp. 530–536, 2002.
[16] D. X. Nguyen and J. Massagu´ e, “Genetic determinants of
cancer metastasis,” Nature Reviews Genetics,v o l .8 ,n o .5 ,p p .
341–352, 2007.
[17] J. S. Michaelson, M. Silverstein, D. Sgroi et al., “The eﬀect
of tumor size and lymph node status on breast carcinoma
lethality,” Cancer, vol. 98, no. 10, pp. 2133–2143, 2003.
[ 1 8 ]F .B e r t u c c i ,R .H o u l g a t t e ,A .B e n z i a n ee ta l . ,“ G e n ee x p r e s s i o n
proﬁling of primary breast carcinomas using arrays of can-
didate genes,” Human Molecular Genetics,v o l .9 ,n o .2 0 ,p p .
2981–2991, 2000.
[19] E. Huang, S. H. Cheng, H. Dressman et al., “Gene expression
predictors ofbreastcanceroutcomes,”TheLancet,vol.361,no.
9369, pp. 1590–1596, 2003.
[ 2 0 ]M .C .A b b a ,H .S u n ,K .A .H a w k i n se ta l . ,“ B r e a s tc a n c e r
molecularsignatures asdetermined by SAGE: correlation with
lymph node status,” Molecular Cancer Research,v o l .5 ,n o .9 ,
pp. 881–890, 2007.
[21] X. Lu, X. Lu, Z. C. Wang, J. D. Iglehart, X. Zhang, and A. L.
Richardson, “Predicting features of breast cancer with gene
expression patterns,” Breast Cancer Research and Treatment,
vol. 108, no. 2, pp. 191–201, 2008.
[22] B. Weigelt, L. F. A. Wessels, A. J. Bosma et al., “No common
denominatorforbreastcancerlymphnodemetastasis,”British
Journal of Cancer, vol. 93, no. 8, pp. 924–932, 2005.
[23] M. J. van de Vijver, Y. D. He, L. J. van ’t Veer et al., “A
gene-expression signature as a predictor of survival in breast
cancer,” The New England Journal of Medicine,vol.347, no.25,
pp. 1999–2009, 2002.
[24] L. Ein-Dor, O. Zuk, and E. Domany, “Thousands of samples
are needed to generate a robust gene list for predicting
outcome in cancer,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 103, no. 15, pp.
5923–5928, 2006.
[25] I. J. Fidler and M. L. Kripke, “Metastasis results from
preexisting variant cells within a malignant tumor,” Science,
vol. 197, no. 4306, pp. 893–895, 1977.
[26] G. Poste and I. J. Fidler, “The pathogenesis of cancer
metastasis,”Nature, vol. 283, no. 5743, pp. 139–146, 1980.
[27] S. Ramaswamy, K. N. Ross, E. S. Lander, and T. R. Golub, “A
molecular signature of metastasis in primary solid tumors,”
Nature Genetics,vol. 33, no. 1, pp. 49–54, 2003.
[28] I. J. Fidler, M. L. Kripke, S. Ramaswamy, K. N. Ross, E. S.
Lander,andT.R.Golub,“Genomicanalysisofprimarytumors
does not address the prevalence of metastatic cells in the
population,” Nature Genetics,vol. 34, no. 1, p. 23, 2003.
[29] D. R. Welch, “Microarrays bring new insights into under-
standing of breast cancer metastasis to bone,” Breast Cancer
Research, vol. 6, no. 2, pp. 61–64, 2004.
[ 3 0 ]Y .K a n g ,P .M .S i e g e l ,W .S h ue ta l . ,“ Am u l t i g e n i cp r o g r a m
mediating breast cancer metastasis to bone,” Cancer Cell,v o l .
3, no. 6, pp. 537–549, 2003.
[31] L.Ding,M.J.Ellis,S.Lietal.,“Genomeremodellinginabasal-
like breast cancer metastasis and xenograft,” Nature, vol. 464,
no. 7291, pp. 999–1005, 2010.
[ 3 2 ]T .S ø r l i e ,C .M .P e r o u ,R .T i b s h i r a n ie ta l . ,“ G e n ee x p r e s -
sion patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications,” Proceedings of the National
Academy of Sciencesof the United States of America, vol.98, no.
19, pp. 10869–10874, 2001.
[33] H. Kennecke, R. Yerushalmi, R. Woods et al., “Metastatic
behavior of breast cancer subtypes,” Journal of Clinical Oncol-
ogy, vol. 28, no. 20, pp. 3271–3277, 2010.
[34] M. Smid, Y. Wang, Y. Zhang et al., “Subtypes of breast cancer
show preferential site of relapse,” Cancer Research,v o l .6 8 ,n o .
9, pp. 3108–3114, 2008.
[ 3 5 ]J .X .Y u ,A .M .S i e u w e r t s ,Y .Z h a n ge ta l . ,“ P a t h w a ya n a l y s i s
of gene signatures predicting metastasis of node-negative
primary breast cancer,” BMC Cancer, vol. 7, article 182, 2007.
[36] F. C. Bidard, J. Y. Pierga, A. Vincent-Salomon, and M. F.
Poupon, “A “class action” against the microenvironment: do
cancer cells cooperate in metastasis?” Cancer and Metastasis
Reviews, vol. 27, no. 1, pp. 5–10, 2008.
[37] K. Hunter, “The intersection of inheritance and metastasis:
the role andimplicationsofgermlinepolymorphismin tumor
dissemination,”Cell Cycle, vol. 4, no. 12, pp. 1719–1721,2005.
[38] M. T. Pletcher, P. McClurg, S. Batalov et al., “Use of a dense
single nucleotide polymorphism map for in silico mapping in
the mouse,” PLoS Biology, vol. 2, no. 12, article e393, 2004.
[39] N. P. S. Crawford, A. Ziogas, D. J. Peel, J. Hess, H. Anton-
Culver,andK.W.Hunter, “GermlinepolymorphismsinSIPA1
are associated with metastasis and other indicators of poor
prognosis in breast cancer,” Breast Cancer Research,v o l .8 ,n o .
2, article R16, 2006.
[ 4 0 ] S .M .H s i e h ,M .P .L o o k ,A .M .S i e u w e r t s ,J .A .F o e k e n s ,a n dK .
W. Hunter, “Distinct inherited metastasis susceptibility exists
for diﬀerent breast cancer subtypes: a prognosis study,” Breast
Cancer Research, vol. 11, no. 5, p. R75, 2009.